Quick Answer
RECURSION PHARMACEUTICALS, INC. reported Operating Income of -$648.13 million for fiscal year 2025.
RECURSION PHARMACEUTICALS, INC. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$648.13M | -35.3% |
| 2024 | -$479.00M | -36.8% |
| 2023 | -$350.06M | -42.5% |
| 2022 | -$245.73M | -34.4% |
| 2021 | -$182.78M | -116.0% |
| 2020 | -$84.61M | -35.5% |
| 2019 | -$62.44M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$172.20M | -75.1% | +2.3% |
| June 30, 2025 | -$176.23M | -75.3% | +7.9% |
| March 31, 2025 | -$191.37M | -98.6% | -94.6% |
| September 30, 2024 | -$98.35M | +1.2% | +2.2% |
| June 30, 2024 | -$100.54M | -23.0% | -4.4% |
| March 31, 2024 | -$96.34M | -37.9% | +3.2% |
| September 30, 2023 | -$99.55M | -59.1% | -21.8% |
| June 30, 2023 | -$81.72M | -23.5% | -17.0% |
- RECURSION PHARMACEUTICALS, INC. showed a decrease of -35.3% in Operating Income compared to the prior fiscal year.
- Over the 2019–2025 period, RECURSION PHARMACEUTICALS, INC.’s operating income has declined by 938.0% (from -$62.44 million to -$648.13 million).
- The most recent figure is from RECURSION PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: